

HAEMONETICS CORP  
Form 8-K  
June 07, 2011

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) June 3, 2011**

**HAEMONETICS CORPORATION**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other jurisdiction  
of incorporation)

**1-14041**  
(Commission  
File Number)

**04-2882273**  
(I.R.S. Employer  
Identification No.)

**400 Wood Road**  
(Address of principal executive offices)

**02184**  
(Zip Code)

Registrant's telephone number, including area code **781-848-7100**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02(c) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On June 6, 2011, Haemonetics Corporation announced that Richard J. Meelia was elected to serve as Non-Executive Chairman of the Board of Directors effective as of June 3, 2011.

Mr. Meelia will receive an annual retainer equal to \$250,000 and initial equity grant valued at \$300,000 and split equally between restricted stock units and non-qualified stock options. His annual retainer will be pro-rated to reflect the remainder of the fiscal year ending March 31, 2012 in which director cash compensation is paid. Mr. Meelia's equity grant consists of a grant of 2,275 restricted stock units and 8,484 non-qualified stock options with an exercise price of \$65.92. These shares will vest one year from the grant date.

**Item 7.01 Regulation FD Disclosure.**

The company's press release announcing the election of Mr. Meelia is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(c) Exhibits

99.1: Press Release of Haemonetics Corporation dated June 6, 2011 announcing the election of Richard J. Meelia Non-Executive Chairman of the Haemonetics Board of Directors.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**HAEMONETICS CORPORATION**  
(Registrant)

Date: June 7, 2011

/s/ Christopher Lindop  
Christopher Lindop, Chief Financial  
Officer  
and VP Business Development

---

**EXHIBIT INDEX**

- 99.1 Press Release of Haemonetics Corporation dated June 6, 2011 announcing the election of Richard J. Meelia Non-Executive Chairman of the Haemonetics Board of Directors.